---
title: "Psych News Alert: Vraylar Now Approved for Full Spectrum of Bipolar I Disorder Symptoms"
description: Yesterday the Food and Drug Administration (FDA) approved Vraylar (cariprazine) for the treatment of depressive episodes in adults with b...
image: https://alert.psychnews.org/hubfs/Imported_Blog_Media/FDA_NewLogo-Jun-24-2025-09-48-32-0835-PM.jpg
---

 5/29/19 12:00 AM

# Vraylar Now Approved for Full Spectrum of Bipolar I Disorder Symptoms

![Picture of Psychiatric News Alert](https://alert.psychnews.org/hs-fs/hubfs/Psych%20News%20Email%20Banners/PN-Blue-Box_rgb.png?width=50&name=PN-Blue-Box_rgb.png) [ Psychiatric News Alert ](https://alert.psychnews.org/author/psychiatric-news-alert)

Share: [facebook-f icon ](http://www.facebook.com/share.php?u=https://alert.psychnews.org/2019/05/vraylar-now-approved-for-full-spectrum.html) [linkedin-in icon ](http://www.linkedin.com/shareArticle?mini=true&url=https://alert.psychnews.org/2019/05/vraylar-now-approved-for-full-spectrum.html) [Twitter icon ](https://twitter.com/intent/tweet?url=https://alert.psychnews.org/2019/05/vraylar-now-approved-for-full-spectrum.html) [pinterest-p icon ](http://pinterest.com/pin/create/link/?url=https://alert.psychnews.org/2019/05/vraylar-now-approved-for-full-spectrum.html) [envelope icon ](mailto:?body=https://alert.psychnews.org/2019/05/vraylar-now-approved-for-full-spectrum.html)

| ![](https://alert.psychnews.org/hs-fs/hubfs/Imported_Blog_Media/FDA_NewLogo-Jun-24-2025-09-48-30-1625-PM.jpg?width=200&height=200&name=FDA_NewLogo-Jun-24-2025-09-48-30-1625-PM.jpg) |  |
| --- | --- |

Yesterday the Food and Drug Administration (FDA) approved Vraylar (cariprazine) for the treatment of depressive episodes in adults with bipolar I disorder. This expanded indication means Vraylar, a dopamine and serotonin partial agonist, is now approved to treat depressive, manic, and mixed episodes of bipolar I disorder. Vraylar, which is manufactured by Allergan, is also approved for the treatment of schizophrenia in adults.

The drug’s expanded indication is based on results from three clinical trials (RGH-MD-53, [RGH-MD-54](https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2018.18070824), and [RGH-MD-56](https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2015.15020164)), which evaluated Vraylar once daily versus placebo in adults with bipolar depression. The primary outcome was change in the Montgomery-Åsberg Depression Rating Scale (MADRS) after six weeks of treatment.

For the three Vraylar dosages studied, the trials found that patients treated with 1.5 mg/day experienced significant improvements in their MADRS score versus placebo. One trial confirmed similar significant findings for the 3 mg daily dose.

“Treating bipolar disorder can be very difficult because people living with the illness experience a range of depressive and manic symptoms, sometimes both at the same time, and this FDA approval gives health care providers a new option to treat the full spectrum of bipolar I disorder symptoms … with just one medication,” Stephen Stahl, M.D., Ph.D., a professor of psychiatry at the University of California, San Diego, said in a [press release](https://www.allergan.com/news/news/thomson-reuters/allergan-and-gedeon-richter-receive-u-s-fda-approv.aspx) from Allergan.

The most commonly reported adverse events in the three trials were nausea, akathisia (an uncontrollable urge to move), restlessness, and other extrapyramidal symptoms (such as muscle spasms, rigidity, slowness of movement, and irregular movements).

FDA approved Vraylar 1.5 mg/day or 3 mg/day for the treatment of depressive episodes in bipolar I disorder. Vraylar 3 mg/day to 6 mg/day is approved for the acute treatment of manic or mixed episodes.

For more information on bipolar I disorder, see the *Psychiatric News* article “[Researchers Sum Up Current Knowledge of Bipolar Disorder, Call for More Study](https://psychnews.psychiatryonline.org/doi/10.1176/appi.pn.2018.3a15).”

*NOTE: The clinical trial results for [RGH-MD-54](https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2018.18070824) and [RGH-MD-56](https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2015.15020164) were published in the* American Journal of Psychiatry. *The results for RHG-MD-53 have not been published yet.*

[![](https://alert.psychnews.org/hubfs/Imported_Blog_Media/Twitter_Bird-Jun-24-2025-09-48-41-6556-PM.png)](https://alert.psychnews.org/hubfs/Imported_Blog_Media/Twitter_Bird-Jun-24-2025-09-48-41-6556-PM.png) 

**[Follow *Psychiatric News* on Twitter!](https://twitter.com/PsychiatricNews)**

[bipolar disorder](https://alert.psychnews.org/tag/bipolar-disorder), [bipolar depression](https://alert.psychnews.org/tag/bipolar-depression), [Allergan](https://alert.psychnews.org/tag/allergan), [cariprazine](https://alert.psychnews.org/tag/cariprazine), [Vraylar](https://alert.psychnews.org/tag/vraylar), [Stephen Stahl](https://alert.psychnews.org/tag/stephen-stahl), [depressive episode](https://alert.psychnews.org/tag/depressive-episode)

## Related posts

[![](https://alert.psychnews.org/hs-fs/hubfs/Imported_Blog_Media/shutterstock_279641462-4.jpg?height=200&name=shutterstock_279641462-4.jpg) ](https://alert.psychnews.org/2015/11/cariprazine-found-to-be-effective-and.html)

[bipolar depression](https://alert.psychnews.org/tag/bipolar-depression), [lurasidone](https://alert.psychnews.org/tag/lurasidone), [quetiapine](https://alert.psychnews.org/tag/quetiapine), [antipsychotics](https://alert.psychnews.org/tag/antipsychotics), [cariprazine](https://alert.psychnews.org/tag/cariprazine), [Vraylar](https://alert.psychnews.org/tag/vraylar)

## [Cariprazine Found to Be Effective and Well-Tolerated for Bipolar Depression](https://alert.psychnews.org/2015/11/cariprazine-found-to-be-effective-and.html)

![Picture of Psychiatric News Alert](https://alert.psychnews.org/hs-fs/hubfs/Psych%20News%20Email%20Banners/PN-Blue-Box_rgb.png?width=50&name=PN-Blue-Box_rgb.png) [Psychiatric News Alert](https://alert.psychnews.org/author/psychiatric-news-alert) 

 11/6/15 12:00 AM

An eight-week, randomized, controlled study published today in AJP in Advance has found that a 1.5...

[ Read more ](https://alert.psychnews.org/2015/11/cariprazine-found-to-be-effective-and.html)

[![](https://alert.psychnews.org/hs-fs/hubfs/Imported_Blog_Media/FDA%20approved_180413006-Jun-24-2025-06-21-25-2525-PM.jpg?height=200&name=FDA%20approved_180413006-Jun-24-2025-06-21-25-2525-PM.jpg) ](https://alert.psychnews.org/2015/09/fda-approves-vraylar-for-treatment-of.html)

[schizophrenia](https://alert.psychnews.org/tag/schizophrenia), [bipolar disorder](https://alert.psychnews.org/tag/bipolar-disorder), [FDA approval](https://alert.psychnews.org/tag/fda-approval), [antipsychotic medication](https://alert.psychnews.org/tag/antipsychotic-medication), [Food and Drug Administration](https://alert.psychnews.org/tag/food-and-drug-administration), [cariprazine](https://alert.psychnews.org/tag/cariprazine), [Vraylar](https://alert.psychnews.org/tag/vraylar)

## [FDA Approves Vraylar for Treatment of Schizophrenia and Bipolar Disorder](https://alert.psychnews.org/2015/09/fda-approves-vraylar-for-treatment-of.html)

![Picture of Psychiatric News Alert](https://alert.psychnews.org/hs-fs/hubfs/Psych%20News%20Email%20Banners/PN-Blue-Box_rgb.png?width=50&name=PN-Blue-Box_rgb.png) [Psychiatric News Alert](https://alert.psychnews.org/author/psychiatric-news-alert) 

 9/21/15 12:00 AM

The Food and Drug Administration (FDA) last week approved Vraylar (cariprazine), a dopamine D2/D3...

[ Read more ](https://alert.psychnews.org/2015/09/fda-approves-vraylar-for-treatment-of.html)

[![](https://alert.psychnews.org/hs-fs/hubfs/Imported_Blog_Media/lighttherapy_iStock-610775376-Jun-24-2025-06-16-33-5244-PM.jpg?height=200&name=lighttherapy_iStock-610775376-Jun-24-2025-06-16-33-5244-PM.jpg) ](https://alert.psychnews.org/2018/03/light-therapy-for-bipolar-depression.html)

[mania](https://alert.psychnews.org/tag/mania), [bipolar disorder](https://alert.psychnews.org/tag/bipolar-disorder), [meta-analysis](https://alert.psychnews.org/tag/meta-analysis), [bipolar depression](https://alert.psychnews.org/tag/bipolar-depression), [hypomania](https://alert.psychnews.org/tag/hypomania), [light therapy](https://alert.psychnews.org/tag/light-therapy)

## [Light Therapy for Bipolar Depression Poses Minimal Risk of Mania Switching](https://alert.psychnews.org/2018/03/light-therapy-for-bipolar-depression.html)

![Picture of Psychiatric News Alert](https://alert.psychnews.org/hs-fs/hubfs/Psych%20News%20Email%20Banners/PN-Blue-Box_rgb.png?width=50&name=PN-Blue-Box_rgb.png) [Psychiatric News Alert](https://alert.psychnews.org/author/psychiatric-news-alert) 

 3/12/18 12:00 AM

Light therapy has been shown to be an effective treatment for bipolar depression, but there have...

[ Read more ](https://alert.psychnews.org/2018/03/light-therapy-for-bipolar-depression.html)

```json
{
  "@context" : "https://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Psychiatric News Alert",
    "url" : "https://alert.psychnews.org/author/psychiatric-news-alert"
  },
  "dateModified" : "2025-06-24T21:48:59.072Z",
  "datePublished" : "2019-05-29T04:00:00.000Z",
  "headline" : "Psych News Alert: Vraylar Now Approved for Full Spectrum of Bipolar I Disorder Symptoms",
  "image" : [ "https://alert.psychnews.org/hubfs/Imported_Blog_Media/FDA_NewLogo-Jun-24-2025-09-48-32-0835-PM.jpg" ],
  "mainEntityOfPage" : {
    "@id" : "https://alert.psychnews.org/2019/05/vraylar-now-approved-for-full-spectrum.html",
    "@type" : "WebPage"
  },
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "url" : "https://alert.psychnews.org/hubfs/PN-Blue-Box.jpg"
    }
  }
}
```